151 related articles for article (PubMed ID: 27781494)
21. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
Wang B; Cai Z; Yao H; Jiao S; Chen S; Yang Z; Huang W; Ren Q; Cao Z; Chen Y; Zhang L; Li Z
Eur J Med Chem; 2023 Jan; 245(Pt 1):114883. PubMed ID: 36343410
[TBL] [Abstract][Full Text] [Related]
23. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
24. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
Mancini AD; Poitout V
Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
[TBL] [Abstract][Full Text] [Related]
25. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
Defossa E; Wagner M
Bioorg Med Chem Lett; 2014 Jul; 24(14):2991-3000. PubMed ID: 24881568
[TBL] [Abstract][Full Text] [Related]
26. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.
Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q
Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621
[TBL] [Abstract][Full Text] [Related]
27. Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-2-yl)propanoic acid scaffold.
Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1404-10. PubMed ID: 26899762
[TBL] [Abstract][Full Text] [Related]
28. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.
Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H
Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571
[TBL] [Abstract][Full Text] [Related]
29. Ligands at Free Fatty Acid Receptor 1 (GPR40).
Hara T
Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
[TBL] [Abstract][Full Text] [Related]
30. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
[TBL] [Abstract][Full Text] [Related]
32. Discovery and development of CPL207280 as new GPR40/FFA1 agonist.
Mach M; Bazydło-Guzenda K; Buda P; Matłoka M; Dzida R; Stelmach F; Gałązka K; Wąsińska-Kałwa M; Smuga D; Hołowińska D; Dawid U; Gurba-Bryśkiewicz L; Wiśniewski K; Dubiel K; Pieczykolan J; Wieczorek M
Eur J Med Chem; 2021 Dec; 226():113810. PubMed ID: 34537444
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and Evaluation of Hypoglycemic Activity of Structural Isomers of ((Benzyloxy)phenyl)propanoic Acid Bearing an Aminobornyl Moiety.
Kuranov SO; Pon Kina DA; Meshkova YV; Marenina MK; Khvostov MV; Luzina OA; Tolstikova TG; Salakhutdinov NF
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175725
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
[TBL] [Abstract][Full Text] [Related]
37. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
38. Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
Christiansen E; Hudson BD; Hansen AH; Milligan G; Ulven T
J Med Chem; 2016 May; 59(10):4849-58. PubMed ID: 27074625
[TBL] [Abstract][Full Text] [Related]
39. The Role and Future of FFA1 as a Therapeutic Target.
Ghislain J; Poitout V
Handb Exp Pharmacol; 2017; 236():159-180. PubMed ID: 27807697
[TBL] [Abstract][Full Text] [Related]
40. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]